$SWKH
SWK Holdings Corp

2024 Q3 Form 10-Q Financial Statement

#000155278124000488 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $10.42M $11.54M
YoY Change 16.25% 21.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.378M $6.997M
YoY Change 36.81% 202.25%
% of Gross Profit
Research & Development $585.0K $520.0K
YoY Change -3.47% -65.54%
% of Gross Profit
Depreciation & Amortization $234.0K $421.0K
YoY Change -64.0% -33.91%
% of Gross Profit
Operating Expenses $585.0K $520.0K
YoY Change -3.47% -65.54%
Operating Profit $4.082M
YoY Change -5.64%
Interest Expense -$847.0K $1.119M
YoY Change -581.25% 208.26%
% of Operating Profit -20.75%
Other Income/Expense, Net
YoY Change
Pretax Income $4.374M $5.430M
YoY Change 7.0% 0.78%
Income Tax $906.0K $1.035M
% Of Pretax Income 20.71% 19.06%
Net Earnings $3.468M $4.395M
YoY Change -22.49% 11.72%
Net Earnings / Revenue 33.29% 38.08%
Basic Earnings Per Share $0.28 $0.35
Diluted Earnings Per Share $0.28 $0.35
COMMON SHARES
Basic Shares Outstanding 12.36M shares 12.47M shares
Diluted Shares Outstanding 12.41M shares 12.53M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.18M $5.549M
YoY Change -44.59% -18.46%
Cash & Equivalents $17.18M $5.549M
Short-Term Investments
Other Short-Term Assets $1.610M $1.859M
YoY Change -8.31% -1.38%
Inventory
Prepaid Expenses
Receivables $6.420M $7.384M
Other Receivables $0.00 $0.00
Total Short-Term Assets $25.21M $14.79M
YoY Change -32.24% 13.17%
LONG-TERM ASSETS
Property, Plant & Equipment $4.816M $5.008M
YoY Change -12.1% -10.54%
Goodwill
YoY Change
Intangibles $220.0K $232.0K
YoY Change -96.82% -96.84%
Long-Term Investments $755.0K $731.0K
YoY Change 655.0% 1138.98%
Other Assets $3.410M $4.504M
YoY Change -15.95% 44.22%
Total Long-Term Assets $296.1M $306.6M
YoY Change 6.25% 10.53%
TOTAL ASSETS
Total Short-Term Assets $25.21M $14.79M
Total Long-Term Assets $296.1M $306.6M
Total Assets $321.3M $321.4M
YoY Change 1.72% 10.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.874M $3.310M
YoY Change 6.44% 11.6%
Accrued Expenses
YoY Change
Deferred Revenue $2.109M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.983M $5.526M
YoY Change -79.88% 84.45%
LONG-TERM LIABILITIES
Long-Term Debt $31.24M $31.08M
YoY Change
Other Long-Term Liabilities $1.622M $1.566M
YoY Change -29.84% -33.7%
Total Long-Term Liabilities $1.622M $1.566M
YoY Change -29.84% -33.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.983M $5.526M
Total Long-Term Liabilities $1.622M $1.566M
Total Liabilities $37.85M $38.17M
YoY Change -1.13% 130.52%
SHAREHOLDERS EQUITY
Retained Earnings -$4.137B -$4.140B
YoY Change -0.25% -0.29%
Common Stock $12.00K $12.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $283.4M $283.2M
YoY Change
Total Liabilities & Shareholders Equity $321.3M $321.4M
YoY Change 1.72% 10.65%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $3.468M $4.395M
YoY Change -22.49% 11.72%
Depreciation, Depletion And Amortization $234.0K $421.0K
YoY Change -64.0% -33.91%
Cash From Operating Activities $6.317M $5.413M
YoY Change 66.24% 14.59%
INVESTING ACTIVITIES
Capital Expenditures $29.00K $21.00K
YoY Change -73.64% -88.52%
Acquisitions
YoY Change
Other Investing Activities $8.606M -$4.347M
YoY Change -28786.67% -129.03%
Cash From Investing Activities $8.577M -$4.368M
YoY Change -6226.43% -129.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.265M -994.0K
YoY Change -115.87% -93.77%
NET CHANGE
Cash From Operating Activities 6.317M 5.413M
Cash From Investing Activities 8.577M -4.368M
Cash From Financing Activities -3.265M -994.0K
Net Change In Cash 11.63M 51.00K
YoY Change -52.01% -98.57%
FREE CASH FLOW
Cash From Operating Activities $6.317M $5.413M
Capital Expenditures $29.00K $21.00K
Free Cash Flow $6.288M $5.392M
YoY Change 70.41% 18.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001089907
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
CY2023Q2 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
183000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
1083000 usd
CY2024Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
57000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39184
dei Entity Registrant Name
EntityRegistrantName
SWK Holdings Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0435679
dei Entity Address Address Line1
EntityAddressAddressLine1
5956 Sherry Lane
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 650
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75225
dei City Area Code
CityAreaCode
(972)
dei Local Phone Number
LocalPhoneNumber
687-7250
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12361850 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5549000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4503000 usd
CY2023Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
733000 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
7384000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
4729000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1859000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1904000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
14792000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
11869000 usd
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13083000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13901000 usd
CY2024Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
265470000 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
274504000 usd
CY2024Q2 us-gaap Derivative Instruments And Hedges
DerivativeInstrumentsAndHedges
2750000 usd
CY2023Q4 us-gaap Derivative Instruments And Hedges
DerivativeInstrumentsAndHedges
2750000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
731000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
48000 usd
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
27052000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
28290000 usd
CY2024Q2 swkh Warrant Assets
WarrantAssets
835000 usd
CY2023Q4 swkh Warrant Assets
WarrantAssets
1759000 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
232000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6487000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5008000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5438000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4504000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3109000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3310000 usd
CY2024Q2 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
usd
CY2024Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
CY2023Q2 swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
CY2023Q2 swkh Net Realized Gain On Exercise Of Warrants
NetRealizedGainOnExerciseOfWarrants
usd
swkh Net Realized Gain On Exercise Of Warrants
NetRealizedGainOnExerciseOfWarrants
usd
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2023Q2 us-gaap Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount
DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
usd
us-gaap Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount
DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
swkh Net Realized Gain On Exercise Of Warrants
NetRealizedGainOnExerciseOfWarrants
usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
usd
us-gaap Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount
DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
usd
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
swkh Derecognition Of Rou Assets To Operating Lease Liabilities Upon Termination Of Lease
DerecognitionOfRouAssetsToOperatingLeaseLiabilitiesUponTerminationOfLease
usd
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Loss Excluding Accrued Interest
FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest
usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
usd
dei Document Type
DocumentType
10-Q
CY2024Q2 us-gaap Assets
Assets
321374000 usd
CY2023Q4 us-gaap Assets
Assets
334254000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3935000 usd
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
2216000 usd
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
9000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5526000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3944000 usd
CY2023Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
4900000 usd
CY2024Q2 us-gaap Unsecured Debt
UnsecuredDebt
31078000 usd
CY2023Q4 us-gaap Unsecured Debt
UnsecuredDebt
30781000 usd
CY2023Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
12350000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1566000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1964000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
38170000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
53939000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12447195 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12447195 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12497770 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12497770 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4423472000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4425104000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4140280000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4144801000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
283204000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
280315000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321374000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
334254000 usd
CY2024Q2 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
10680000 usd
CY2023Q2 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
9278000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
21399000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
18538000 usd
CY2024Q2 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
804000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
301000 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
36000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
103000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
69000 usd
CY2024Q2 us-gaap Revenues
Revenues
11541000 usd
CY2023Q2 us-gaap Revenues
Revenues
9497000 usd
us-gaap Revenues
Revenues
22585000 usd
us-gaap Revenues
Revenues
18908000 usd
CY2024Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
4074000 usd
CY2023Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
9397000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5771000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5771000 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
1119000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
363000 usd
us-gaap Interest Expense
InterestExpense
2375000 usd
us-gaap Interest Expense
InterestExpense
545000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
520000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1509000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2228000 usd
CY2024Q2 swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-4900000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-4900000 usd
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
421000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
637000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
935000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1285000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2923000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2997000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5607000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5537000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
-1613000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
-4673000 usd
us-gaap Costs And Expenses
CostsAndExpenses
-2350000 usd
us-gaap Costs And Expenses
CostsAndExpenses
-9995000 usd
CY2024Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
226000 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
399000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
131000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-583000 usd
CY2024Q2 swkh Net Realized Gain On Exercise Of Warrants
NetRealizedGainOnExerciseOfWarrants
656000 usd
swkh Net Realized Gain On Exercise Of Warrants
NetRealizedGainOnExerciseOfWarrants
513000 usd
CY2024Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
3000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-228000 usd
CY2024Q2 us-gaap Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount
DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
2495000 usd
us-gaap Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount
DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
2495000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
437000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
316000 usd
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
524000 usd
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
502000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5430000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5388000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5785000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
9914000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1035000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1454000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1264000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1345000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
4395000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3934000 usd
us-gaap Profit Loss
ProfitLoss
4521000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12457000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12741000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12466000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12787000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12528000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12534000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12830000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
280315000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
111000 usd
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
999000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
126000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
279553000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
249000 usd
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
950000 usd
CY2024Q2 swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
-43000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
4395000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
283204000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279929000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
35000 usd
CY2023Q1 swkh Effect Of Adoption Of Accounting Standard
EffectOfAdoptionOfAccountingStandard
-9683000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
531000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
4635000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
274385000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
164000 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
4599000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3934000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
273884000 usd
us-gaap Profit Loss
ProfitLoss
4521000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
9397000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5771000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
261000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
156000 usd
swkh Noncash Interest Expense
NoncashInterestExpense
491000 usd
swkh Noncash Interest Expense
NoncashInterestExpense
168000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1239000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1316000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
131000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-583000 usd
swkh Net Realized Gain On Exercise Of Warrants
NetRealizedGainOnExerciseOfWarrants
513000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-228000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-4900000 usd
us-gaap Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount
DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
2495000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-327000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-516000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
-2592000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
-2297000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
904000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
957000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
360000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
199000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
935000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1285000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-2655000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-1287000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
150000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
792000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-900000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-354000 usd
us-gaap Deferred Income Period Increase Decrease
DeferredIncomePeriodIncreaseDecrease
2207000 usd
us-gaap Deferred Income Period Increase Decrease
DeferredIncomePeriodIncreaseDecrease
-3000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9843000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5388000 usd
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
13942000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
574000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
7446000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
13101000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
11693000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
3041000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
13000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
17000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
191000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4813000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3708000 usd
swkh Net Settlement For Employee Taxes On Restricted Stock And Options
NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions
-43000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-12350000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-2445000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
872000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1950000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5130000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14343000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8447000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
313000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
649000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5236000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6156000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5549000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6805000 usd
swkh Derecognition Of Rou Assets To Operating Lease Liabilities Upon Termination Of Lease
DerecognitionOfRouAssetsToOperatingLeaseLiabilitiesUponTerminationOfLease
82000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zQ9hzvHV4X7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zlsK9tNWyS82">Use of Estimates</span></i></b></span><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; allowance for credit losses; valuation or impairment of long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 number
CY2024Q1 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
10719000 usd
CY2024Q1 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
279000 usd
CY2024Q1 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
46000 usd
CY2024Q1 us-gaap Revenues
Revenues
11044000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
126000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2024Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
261272000 usd
CY2024Q1 us-gaap Assets
Assets
322337000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4144675000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
279553000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
4395000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3934000 usd
us-gaap Profit Loss
ProfitLoss
4521000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12457000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12741000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12466000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12787000 shares
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
71000 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
44000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
68000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
43000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12528000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12785000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12534000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12830000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
159000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
118000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
161000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
119000 shares
CY2024Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
278553000 usd
CY2023Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
288405000 usd
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13083000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13901000 usd
CY2024Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
265470000 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
274504000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13901000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11846000 usd
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Loss Excluding Accrued Interest
FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest
11786000 usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
5182000 usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-682000 usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
6000000 usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
11846000 usd
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13083000 usd
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11104000 usd
CY2024Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
278553000 usd
CY2023Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
288405000 usd
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13083000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
13901000 usd
CY2024Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
265470000 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
274504000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Year One Originated Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear
77925000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Year Two Originated Fiscal Year Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear
63420000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Year Three Originated Two Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear
49416000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Year Four Originated Three Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear
28295000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Year Five Originated Four Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear
37503000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Originated More Than Five Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear
31846000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Before Allowance For Credit Loss
FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss
288405000 usd
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
450000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
218000 usd
CY2024Q2 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
232000 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
23363000 usd
CY2023Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
6487000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
45000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
45000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
45000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
45000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
29000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
232000 usd
CY2023Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
45000000.0 usd
CY2023Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
60000000.0 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
32969000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
32969000 usd
CY2024Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1891000 usd
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2188000 usd
CY2024Q2 us-gaap Unsecured Debt
UnsecuredDebt
31078000 usd
CY2023Q4 us-gaap Unsecured Debt
UnsecuredDebt
30781000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
32969000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
32969000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
134000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
125000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
259000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
222000 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
17000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
23000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
32000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
24000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
151000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
148000 usd
us-gaap Lease Cost
LeaseCost
291000 usd
us-gaap Lease Cost
LeaseCost
246000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
283000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
456000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
461000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
465000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
405000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
272000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2342000 usd
CY2024Q2 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
804000 usd
CY2023Q2 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
183000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
1083000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
301000 usd
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
2216000 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
9000 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2216000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 number
CY2024Q2 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
11484000 usd
CY2024Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
57000 usd
CY2024Q2 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
4074000 usd
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5771000 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
1119000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
520000 usd
CY2024Q2 swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-4900000 usd
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
421000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2923000 usd
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3817000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1035000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
4395000 usd
CY2023Q2 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
9461000 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
36000 usd
CY2023Q2 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-682000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
363000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1509000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
637000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2997000 usd
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
715000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1454000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3934000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
22482000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
103000 usd
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
9397000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5771000 usd
us-gaap Interest Expense
InterestExpense
2375000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050000 usd
swkh Change In Fair Value Of Acquisitionrelated Contingent Consideration
ChangeInFairValueOfAcquisitionrelatedContingentConsideration
-4900000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
935000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5607000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3435000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1264000 usd
us-gaap Profit Loss
ProfitLoss
4521000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
18839000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
69000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
us-gaap Interest Expense
InterestExpense
545000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2228000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1285000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5537000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-81000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1345000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd

Files In Submission

Name View Source Status
0001552781-24-000488-index-headers.html Edgar Link pending
0001552781-24-000488-index.html Edgar Link pending
0001552781-24-000488.txt Edgar Link pending
0001552781-24-000488-xbrl.zip Edgar Link pending
e24328001.jpg Edgar Link pending
e24328_ex31-1.htm Edgar Link pending
e24328_ex31-2.htm Edgar Link pending
e24328_ex32-1.htm Edgar Link pending
e24328_ex32-2.htm Edgar Link pending
e24328_swkh-10q.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
e24328_swkh-10q_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
swkh-20240630.xsd Edgar Link pending
swkh-20240630_cal.xml Edgar Link unprocessable
swkh-20240630_def.xml Edgar Link unprocessable
swkh-20240630_lab.xml Edgar Link unprocessable
swkh-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable